InMed Pharmaceuticals Inc (INM)

[Fress]

A Differentiated Cannabinoid-Therapeutics Company
U N L O C K I N G C A N N A B I N O I D M E D I C I N E S
Fully integrated cannabinoid-based biopharmaceutical company that
leverages proprietary platform technologies to develop novel therapeutics
for the treatment of diseases with high unmet medical needs
Explores the potential of all 90+ cannabinoid compounds,
NOT just THC & CBD
Selects specific cannabinoids (or combinations) that have
potential to play a role in regulating specific diseases
Biosynthesizes cannabinoids that are biologically identical
to those produced by the plant
Develops innovative, topically applied therapies for
diseases with high unmet medical needs


A Differentiated Cannabinoid-Therapeutics Company
Employs a highly scientific approach to designing and developing
prescription medicines, which will help unlock the full potential of
cannabinoid pharmaceuticals.

BioInformatics Platforms Algorithms that work to target cured for diseases with cannabinoids:

• A computer-assisted drug candidate
selection process for high-probability
targets
• Pulls information from publicly
available databases together with
internal cannabinoid drug know-how

Biosynthesis
Process
• Designed to enable manufacturing
any of the 90+ cannabinoids
• End products are designed to be bioidentical to the naturally-occurring
cannabinoids

IMLFF